Physician profile
David Saperstein
NPI 1871585711
$135,373.61
in general payments reported to CMS, 2019-2025
47 companies · $669 in 2025
The $669 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26K · 2020: $14K · 2021: $21K · 2022: $28K · 2023: $22K · 2024: $23K · 2025: $669.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $25K · Food and Beverage: $6,069 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,030 · Honoraria: $6,000 · Travel and Lodging: $3,388 · Debt Forgiveness: $60.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $24,619.50 |
| Food and Beverage | $6,069.08 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,030.00 |
| Honoraria | $6,000.00 |
| Travel and Lodging | $3,388.45 |
| Debt Forgiveness | $60.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $71,433.30 | 2019-2024 | Gamunex-C |
| Csl Behring | $11,574.17 | 2019-2025 | Hizentra |
| Takeda Pharmaceuticals U.S.A., INC. | $10,162.31 | 2022-2025 | Hyqvia |
| Ucb, INC. | $9,719.61 | 2022-2025 | Zilbrysq, Rystiggo, Briviact |
| Alnylam Pharmaceuticals INC. | $8,626.38 | 2020-2023 | Onpattro |
| Pfizer INC. | $6,580.54 | 2021-2025 | |
| Akcea Therapeutics, INC. | $4,374.33 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $3,633.52 | 2019-2025 | Ultomiris |
| Shire North American Group INC | $3,182.76 | 2019 | |
| Octapharma USA, INC. | $1,033.20 | 2021 | |
| Argenx US, INC. | $937.26 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Abbvie INC. | $738.15 | 2021-2025 | Ubrelvy, Qulipta |
| Tersera Therapeutics LLC | $717.58 | 2023-2024 | Quzyttir |
| Amgen INC. | $373.53 | 2019-2022 | |
| Lundbeck LLC | $266.60 | 2019-2025 | Vyepti |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Saperstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.